The psychedelic sector never sits still. Here is what happened during the week of August 25–31, 2025, and why each story matters for the companies and investors we track.
AbbVie / Gilgamesh Pharmaceuticals (ABBV): AbbVie to acquire Gilgamesh's psychedelic candidate bretisilocin for up to $1.2 billion
AbbVie agreed to acquire Gilgamesh Pharmaceuticals' lead asset bretisilocin (GM-2505), a short-acting 5-HT2A agonist and serotonin releaser in Phase 2 development for major depressive disorder, in a deal worth up to $1.2 billion in upfront and milestone payments. A Phase 2a trial had shown a single 10 mg dose meaningfully reduced depressive symptoms versus a low-dose comparator. As one of the largest big-pharma commitments to a psychedelic asset to date, the deal was widely read as validation for the sector and lifted publicly traded peers.
Source: news.abbvie.com
Incannex Healthcare (IXHL): Incannex reports positive Phase 2 results for PSX-001 psilocybin therapy in generalized anxiety disorder
Incannex Healthcare reported positive Phase 2 data for PSX-001, a psilocybin-assisted psychotherapy for generalized anxiety disorder, in a 73-patient randomized, placebo-controlled trial using two 25 mg dosing sessions. Roughly 44% of PSX-001 patients achieved at least a 50% reduction in anxiety scores and 27% reached remission, a remission rate more than five times that of placebo, with no serious adverse events and only one withdrawal. The clean efficacy and safety profile advances Incannex's psilocybin program toward late-stage development.
Source: globenewswire.com
atai Life Sciences (ATAI): atai to participate in multiple September 2025 investor conferences
atai Life Sciences said management would appear at several investor conferences in September 2025. The circuit gave the company a platform to make its case to institutional investors as it advanced its planned strategic combination with Beckley Psytech, which it had guided toward a shareholder-approval stage in Q4 2025 following July's positive BPL-003 Phase 2b topline. It is an investor-relations event rather than a clinical catalyst.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.